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pathogenic mutations and related chondrodysplasia phenotypes
Thatiane Yoshie Kanazawa, Luciana Cardoso Bonadia and Denise Pontes Cavalcanti
Grupo de Displasias Esqueléticas, Departamento de Genética Médica, Faculdade de Ciências Médicas,
Universidade Estadual de Campinas, Campinas, SP, Brazil.
Abstract
Mutations in the FGFR3 gene cause the phenotypic spectrum of FGFR3 chondrodysplasias ranging from lethal
forms to the milder phenotype seen in hypochondroplasia (Hch). The p.N540K mutation in the FGFR3 gene occurs in
~70% of individuals with Hch, and nearly 30% of individuals with the Hch phenotype have no mutations in the
FGFR3, which suggests genetic heterogeneity. The identification of a severe case of Hch associated with the typical
mutation c.1620C > A and the occurrence of a c.1150T > C change that resulted in a p.F384L in exon 10, together
with the suspicion that this second change could be a modulator of the phenotype, prompted us to investigate this hy-
pothesis in a cohort of patients. An analysis of 48 patients with FGFR3 chondrodysplasia phenotypes and 330
healthy (control) individuals revealed no significant difference in the frequency of the C allele at the c.1150 position (p
= 0.34). One patient carrying the combination `pathogenic mutation plus the allelic variant c.1150T > C’ had a typical
achondroplasia (Ach) phenotype. In addition, three other patients with atypical phenotypes showed no association
with the allelic variant. Together, these results do not support the hypothesis of a modulatory role for the c.1150T > C
change in the FGFR3 gene.
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The FGFR3 protein is encoded by a gene of the same
name that has been extensively studied because of its role in
the regulation of linear bone growth. Mutations in this gene
cause the phenotypic spectrum of FGFR3 chondrodys-
plasias that classically include hypochondroplasia (Hch),
achondroplasia (Ach), thanatophoric dysplasia types I and
II (TDI and TDII) and SADDAN (Severe Achondroplasia
with Developmental Delay and Acanthosis Nigricans)
(Warman et al., 2011).
The mutations c.1620C > A and c.1620C > G in exon
13 of the FGFR3 gene both lead to the p.N540K substitu-
tion, a mutation found in 50-70% of individuals with Hch
(Bellus et al., 2000). Other mutations in the FGFR3 gene
associated with Hch account for ~2% of the cases (Cas-
tro-Feijóo et al., 2008). For ~30% of individuals with the
Hch phenotype no mutations have been found in the
FGFR3 gene, suggesting that this condition is clinically
and genetically heterogeneous (Bonaventure et al., 1996).
The diagnosis of Hch is usually suspected or established at
school age when short stature plus clinical and radiological
changes become evident (Spranger et al., 2012). However,
in cases where the phenotype is more severe, the diagnosis
can be made already in the neonatal period (Karadimas et
al., 2006).
The identification of a severe case of Hch diagnosed
in the neonatal period associated with a combination of the
typical mutation (c.1620C > A) in exon 13 and the c.1150T
> C change (p.F384L) in exon 10, together with the suspi-
cion that the change in exon 10 could modulate the pheno-
type (Trujillo-Tiebas et al., 2009), prompted us to investi-
gate this hypothesis in a cohort of patients with FGFR3
chondrodysplasia phenotypes.
We studied 48 patients with FGFR3 chondrodys-
plasia phenotypes. All subjects provided formal informed
consent prior to enrollment, and this study was approved by
an institutional Committee for Ethics in Research (protocol
no. 992/2007). Blood samples were collected and genomic
DNA was extracted using a standard phenol-chloroform
method. The molecular diagnosis was done by direct se-
quencing after PCR amplification of the exons related to
the respective phenotypes. The amplified products were
purified and sequenced using an ABI3500XL® sequencer
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in conjunction with BigDye v.3.1 sequencing kits (Applied
Biosystems, Foster City, CA, USA). The data were pro-
cessed using ABI software and analyzed using CodonCode
Aligner 4.1.1. Exon 10 was sequenced in all cases. In addi-
tion, exons 7, 13 and 15 related to the TDI, Hch and TDII
phenotypes, respectively, were sequenced in patients with
the respective phenotypes. Patients with Ach had no other
exon sequenced since the hot spot for this phenotype is lo-
cated in exon 10. Table 1 shows the eight pathogenic muta-
tions identified in the 48 patients studied.
Two of the 48 patients presented the c.1150T > C
change in addition to the pathogenic mutation. One of these
two patients had Hch because of the c.1620C > A mutation
and was diagnosed in the first months of life because of the
severity of his phenotype (birth length of 44 cm plus corpo-
ral disproportion with rhizomelic shortening of limbs at
birth). As his diagnosis was initially doubtful (mild Ach or
severe Hch), exons 10 and 13 were analyzed. The second
patient had a typical Ach phenotype (c.1138G > A). In both
cases, the c.1150T > C change was inherited, but without
apparent phenotypic consequences in the respective par-
ents. Paternal inheritance was confirmed in the patient with
Hch and maternal inheritance in the patient with Ach. Mo-
lecular cloning was used to determine whether this change
was cis or trans in relation to the pathogenic mutation. In
the Ach patient, the c.1150T > C change was in trans with
the c.1138G > A mutation. A haplotype analysis was not
feasible in the patient with Hch because of the distance
(1,447 bp) between the two changes in the FGFR3 gene.
With regard to phenotype, we identified four atypical
patients: one with Ach (c.1138G > A) associated with cor-
poral asymmetry, mental retardation and acanthosis
nigricans, two with severe Hch (one with c.1620C > A and
the other with c.1620C > G, and clinical and radiological
manifestations in the neonatal period) and one with TD1
(c.742C > T) and long-term survival. Except for the patient
with Hch already described, no other patient among these
three atypical individuals had the allelic variant
c.1150T > C.
For comparison, we also sequenced exon 10 of the
FGFR3 in 330 healthy control subjects. These control sam-
ples consisted of DNA extracted from the cord blood of
healthy newborns. The c.1150T > C change was found in
four individuals. As Hch is usually not apparent in the new-
born period, for all these four controls with the c.1150T > C
change the Hch hot spots (exons 3, 5, 7, 9, 12, 13 and 15)
were also examined and no mutation was found. Table 2
shows the frequencies of the C allele in the control group
and patients, as well as the p value (Fischer test) for the
comparison between the two groups.
Trujillo-Tiebas et al. (2004) reported the presence of
a c.1150T > C change in two families. In one family, the
change was found in a patient with severe but unspecified
skeletal dysplasia. Although unaffected, the patients father
and grandmother displayed subtle symptoms. No other in-
formation about the patients specific mutation was pro-
vided. In the other family, the change was found in a patient
with Hch, along with the most common mutation (c.1620C
> A), and in his mother who was unaffected by the skeletal
dysplasia but presented some skeletal signs. An analysis of
194 chromosomes from individuals of the general popula-
tion detected this change in one chromosome (0.5%). These
authors suggested an additive pathological effect of this
change in the FGFR3 receptor and reported another af-
fected individual found in a series of prenatal cases. The fa-
ther carried the same change (c.1150T > C in FGFR3) as
the abortus, but with no apparent clinical sign (Trujillo-
Tiebas et al., 2009).
In the present study, the presence of a c.1150T > C
change in two patients in a relatively small sample appears
to be a stochastic event. In addition, there was no signifi-
cant difference in the frequency of the C allele between the
controls and patients. The frequency of the C allele in the
control group (0.6%) was the same as that found in a British
population (0.6% or one C allele in 178 chromosomes) ac-
cording to the 1000 Genomes Project (Abecasis et al.,
2012). Interestingly, the frequency of the C allele was 3%
(three C alleles in 100 chromosomes) among individuals of
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Table 1 - Mutations related to their respective phenotypes in 48 patients
with the FGFR3 phenotype.
Clinical
diagnosis
Number of
patients
Mutation
Nucleotide
change
Amino acid
change
Ach 27 c.1138G > A* G380R
1 c.1138G > C
Hch 5 c.1620C > A* N540K
2 c.1620C > G
TDI 7 c. 742C > T R248C
2 c. 746C > G S249C
2 c.1118A > G Y373C
TDII 2 c.1948A > G K650E
*One patient also carried the c.1150T > C change. Ach – achondroplasia,
Hch – hypochondroplasia, TDI and TDII – thanatophoric dysplasia types I
and II, respectively.
Table 2 - Frequency of the c.1150T > C change in both - control individu-
als and patients with pathogenic mutations in the FGFR3.
c.1150T > C change
(p.F384L)
Frequency of the
mutated allele
(%)
p
Positive Negative
Controls 4 326 0.6 0.34
Patients 2 46 2.2
Turkish descent but was uncommon among those of Ger-
man descent (no C alleles in 100 chromosomes) (Golla et
al., 1997).
Although the c.1150T > C mutation leads to a phenyl-
alanine for leucine substitution at position 384 in the amino
acid sequence, this change apparently does not affect recep-
tor function. Both of these amino acids are nonpolar and
their substitution does not change the molecular character-
istics of the transmembrane domain nor the hydrophobicity
of this structure (Adzhubei et al., 2010). Moreover, leucine
is present in the bovine FGFR3 homolog, which indicates a
normal FGFR3 protein function (Golla et al., 1997).
In conclusion, the data here presented do not support
the hypothesis of a modulatory role for the c.1150T > C
change in the FGFR3 gene. The more severe phenotype of
the patient with Hch reported here was apparently related to
the known phenotypic heterogeneity of this condition
rather than to any modulatory effect of the c.1150T > C
change. We suggest that this phenotypic heterogeneity oc-
curs by chance or via another, as yet unknown, modulatory
mechanism.
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